Announced Date: 2025-12-15 (December 15, 2025)
Licensor (Seller): Shanghai Scizeng Medical Technology, a subsidiary of Changchun GeneScience Pharmaceutical (China)
Licensee (Buyer): Yarrow Bioscience, backed by RTW Investment (US)
.
Asset Name: GenSci098, GS-098 (YB-101)
Asset Modality: humanized monoclonal antibody （mAb）
Asset Target: thyroid-stimulating hormone receptor (TSHR)
Potential Indication: Graves’ Disease and Thyroid Eye Disease
Current Stage:
.
Scope of Authority:
Agreement grants Yarrow Bioscience, Inc. exclusive global ex-China rights to develop and commercialize GS-098 (YB-101) for Graves’ disease (GD) and thyroid eye disease (TED).
.
Payment Detail:
GeneScience will receive:
upfront payment of US$70 million, and near-term development milestone US$50 million,
up to US$1.365 billion milestone payments,
10% plus royalties on potential future product sales in licensed territories.
.
Link:
.
Note:
Chinese Name
Changchun GeneScience Pharmaceutical , 长春金赛生物
Shanghai Scizeng Medical Technology, 上海赛增医疗
